60 DEGREES PHARMACEUTICALS, INC.

SXTP · Nasdaq · SIC 2834: Pharmaceutical Preparations
74
SEC Filings

Business Summary

PART I Item 1. Description of Business. Overview We are a specialty pharmaceutical company with a goal of using cutting-edge biological science and applied research to further develop and commercialize new therapies for the prevention and treatment of infectious diseases. We have successfully achieved regulatory approval of Arakoda, a malaria preventative treatment that has been on the market since late 2019. Currently, 60Ps pipeline under development covers development programs for vector-borne...

Next Earnings

Q2 FY2026 — expected 2026-09-12

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionSXTPdiscussed_in_filing Cybersecurity
topic_mentionSXTPdiscussed_in_filing Trusted Computing
topic_mentionSXTPdiscussed_in_filing Blockchain & Crypto
topic_mentionSXTPdiscussed_in_filing Supply Chain
topic_mentionSXTPdiscussed_in_filing Regulation
topic_mentionSXTPdiscussed_in_filing Healthcare & Bio
topic_mentionSXTPdiscussed_in_filing Sovereign & Government
topic_mentionSXTPdiscussed_in_filing Cybersecurity
topic_mentionSXTPdiscussed_in_filing Trusted Computing
topic_mentionSXTPdiscussed_in_filing Blockchain & Crypto
topic_mentionSXTPdiscussed_in_filing Supply Chain
topic_mentionSXTPdiscussed_in_filing Regulation
topic_mentionSXTPdiscussed_in_filing Healthcare & Bio
topic_mentionSXTPdiscussed_in_filing Sovereign & Government
topic_mentionSXTPdiscussed_in_filing Cybersecurity
topic_mentionSXTPdiscussed_in_filing Trusted Computing
topic_mentionSXTPdiscussed_in_filing Blockchain & Crypto
topic_mentionSXTPdiscussed_in_filing Supply Chain
topic_mentionSXTPdiscussed_in_filing Regulation
topic_mentionSXTPdiscussed_in_filing Healthcare & Bio

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-302025-12-310001554855-26-000467EDGAR80K words
2025-03-272024-12-310001013762-25-003343EDGAR—
2024-04-012023-12-310001213900-24-028577EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-132025-09-300001554855-25-002032EDGAR32K words
2025-08-132025-06-300001554855-25-001009EDGAR—
2025-05-152025-03-310001213900-25-043779EDGAR—
2024-11-142024-09-300001213900-24-098195EDGAR—
2024-08-142024-06-300001213900-24-068673EDGAR—
2024-05-152024-03-310001213900-24-043323EDGAR—
2023-11-202023-09-300001213900-23-088610EDGAR—
2023-08-252023-06-300001213900-23-070884EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-200001213900-26-032352EDGAR1K words
2026-03-130001213900-26-027756EDGAR—
2026-03-120001213900-26-027008EDGAR—
2026-02-120001213900-26-015239EDGAR—
2026-01-230001213900-26-007330EDGAR—
2026-01-210001213900-26-006179EDGAR—
2026-01-080001213900-26-002359EDGAR—
2025-10-100001213900-25-098131EDGAR—
2025-09-090001213900-25-085853EDGAR—
2025-09-050001213900-25-085040EDGAR—

74 total filings indexed. 53 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC. AEON — AEON Biopharma, Inc.

Company Identity

CIK0001946563
TickerSXTP
ExchangeNasdaq
SIC2834: Pharmaceutical Preparations
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: e3642a119b23f67fc7acc5cf2e350c4706d6eb30ad0678df35fda506adfa499c
parent: 0b81ea2226ffc67be2761f2f08f84056d817f54bf6502af3bec73052124efe7c
content hash: 5b5cd9d39867cc4c0cf8536b44f71d646912d526287566fdeb394062d9f676af
signed: 2026-04-13T04:47:42.054Z
sources: 11 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf